Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies.
At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
Pharmaceutical Technology on MSN
Quintessence debuts first ‘living’ artificial cell for CGT bio-separation
The technology is designed to simplify the bio-separation process while reducing manufacturing costs.
Zacks Investment Research on MSN
IBRX stock jumps on progress in NK cell therapy production
Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...
LONDON--(BUSINESS WIRE)--Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ ...
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results